Ligand-Mediated Gastrointestinal Targeting

  • John Woodley


This chapter will describe the rationale for drug targeting to the gastrointestinal (GI) tract, why it is important, and what the objectives of such targeting are. The approaches used to achieve these targeting objectives using ligands will be considered and discussed in detail. It it is important to consider some of the pharmaceutical issues involved, such as the type of vehicles to which ligands can be usefully attached. It should be stressed that at the current time, much of the work in this area is theoretical and experimental, with studies in cell culture systems or animals, and has yet to be transferred to man, let alone into pharmaceutical products on the market. In many cases, costs and regulatory considerations may make it prohibitive for the pharmaceutical industry to adopt some of the most interesting ideas emanating from the research laboratories.


Wheat Germ Agglutinin Oral Vaccine Oral Drug Delivery Therapeutic Peptide Sulfhydryl Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. Pappo, T.H. Ermak and H.J. Steger. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer’s patch M cells. Immunology 73: 277–280 (1991).Google Scholar
  2. 2.
    J.F. Woodley and B. Naisbett. The potential of lectins for delaying the intestinal transit of drugs. Proc. Int. Symp. Contr. Rel. Bioact. Mater. 15: 125–126 (1988).Google Scholar
  3. 3.
    B. Naisbett and J. Woodley. The potential use of tomato lectin for oral drug delivery. 3. Bioadhesion in vivo. Int. J. Pharm. 114: 227–236 (1995).CrossRefGoogle Scholar
  4. 4.
    M.J. Montisci, A. Dembri, G. Giovannuci, H. Chacun, D. Duchene and G. Ponchel. Gastrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum L. and Lotus tetragonolobus lectin-PLA microsphere conjugates in rats. Pharm. Res. 18: 829–837 (2001).CrossRefGoogle Scholar
  5. 5.
    Lehr, C.-M,. A. Pustzai. “The potential of bioadhesive lectins for the delivery ofGoogle Scholar
  6. peptide and protein drugs to the gastrointestinal tract.“ In Lectins:Biomedicalperspectives,A.Pusztai, S.Bardocz, ed. London and Bristol: Taylor and Francis, 1995.Google Scholar
  7. 6.
    C.-M. Lehr, F.G.J. Poelma, H.E. Junginger and J.J. Tukker. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int. J. Pharm. 70: 235–240 (1991).CrossRefGoogle Scholar
  8. 7.
    N. Hussain, P.U. Jani and A.T. Florence. Enhanced oral uptake of tomato lectin- conjugated nanoparticles in the rat. Pharm. Res. 14: 613–618 (1997).CrossRefGoogle Scholar
  9. 8.
    N. Foster, M.A. Clark, M.A. Jepson and B.H. Hirst. Ulex europaeus 1 lectin targets microspheres to mouse Peyer’s patch M- cells in vivo. Vaccine 16: 536–541 (1998).CrossRefGoogle Scholar
  10. 9.
    M.A. Clark, B.H. Hirst and M.A. Jepson. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 43: 207–223 (2000).CrossRefGoogle Scholar
  11. 10.
    H. Chen, V. Torchilin and R. Langer. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. J. Cont. Rel. 42: 263–272 (1996).CrossRefGoogle Scholar
  12. 11.
    S. Wrôblewski, P. Kopéckova, B. Rihovâ and J. Kope6ek. Lectin-HPMA copolymer conjugates-drug carriers for gastrointestinal tract targeting. Proc. Int. Symp. Contr. Rel. Bioact. Mater. 25: 768–769 (1998).Google Scholar
  13. 12.
    M. Wirth, A. Fuchs, M. Wolf, B. Ertl and F. Gabor. Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Pharm. Res. 15: 1031–1037 (1998).CrossRefGoogle Scholar
  14. 13.
    S. Wroblewski, M. Berenson, P. Kopeckova and J. Kopecek. Potential of lectin-N-(2- hydroxypropyl)methacrylamide copolymer-drug conjugates for the treatment of pre-cancerous conditions. J. Cont. Rel. 74: 283–293 (2001).CrossRefGoogle Scholar
  15. 14.
    E.C. Lavelle. Targeted delivery of drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Car. Syst. 18: 341–386 (2001).Google Scholar
  16. 15.
    N. Hussain and A.T. Florence. Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm. Res. 15: 153–156 (1998).CrossRefGoogle Scholar
  17. 16.
    D. Ayelet, P. Kopeckovâ, T. Minko, A. Rubinstein and J. Kope6ek. The involvement of endogenous lectins in mediating the antitumor activity of targetable HPMA copolymer-doxorubicin conjugates in human colon adenocarcinoma and hepatoma cells. Pharm. Res. In press: (2002).Google Scholar
  18. 17.
    J. Alsenz, G.J. Russell-Jones, S. Westwood, B. Levet-Trafit and P.C. de Smidt. Oral absorption of peptides through the cobalamin (vitamin B 12) pathway in the rat intestine. J. Cont. Rel. 17: 825–832 (2000).Google Scholar
  19. 18.
    A. Bernkop-Schnürch, V. Schwarz and S. Steininger. Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm. Res. 16: 876–881 (1999).CrossRefGoogle Scholar
  20. 19.
    M.K. Marschütz, P. Caliceti and A. Bernkop-Schnürch. Design and in vitro evaluation of an oral delivery system for insulin. Pharm. Res. 17: 1468–1474 (2000).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • John Woodley
    • 1
  1. 1.Faculté des Sciences PharmaceutiquesToulouseFrance

Personalised recommendations